



1 June 2010  
EMA/CVMP/334379/2010  
Veterinary Medicines and Product Data Management

## Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents

May 2010

The CVMP Monthly Report includes statistical data for the current and previous two years on Scientific Advice, Initial Evaluations, Variations, Line Extensions, Renewals, MRLs Initial Evaluations and MRLs Extensions/Modifications and Arbitration and Referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted Guidelines and other public documents.

### Applications for Medicinal Products for Veterinary Use and Maximum Residue Limits (MRLs)

Scientific Advice Requests					
	95-07	2008	2009	2010	Total
Submitted	58	5	11	13	87

Initial Evaluation					
	95-07	2008	2009	2010	Total
Full (Submitted)	97	13	14	7	131
Abridged/ Generics (Submitted)	7	3	1	2	13
Withdrawals	11	1	0	0	12
Positive Opinions	78	13	13	0	104
Negative Opinions	1	0	0	0	1

Marketing Authorisations					
	95-07	2008	2009	2010	Total
Granted	75	13	12	4	104
Withdrawals	1	1	0	3	5
Not renewed	2	0	0	0	2

Extensions - Annex II Applications					
	95-07	2008	2009	2010	Total
Submitted	56	4	12	1	73
Withdrawals	1	1	1	1	4
Positive Opinions	33	7	7	4	51
Negative Opinions	0	0	0	0	0



<b>Variations – Applications submitted</b>					
	95-07	2008	2009	2010	Total
Type IA	291	23	32	34	468
Type IB		25	41	22	
Type II	158	52	40	13	263
Transfers	9	2	3	0	14

<b>Renewals</b>					
	95-07	2008	2009	2010	Total
Submitted	43	7	18	5	73
Positive Opinions	40	8	15	7	70
Negative Opinions	0	0	0	0	0

<b>Arbitrations and Community Referrals</b>					
	95-07	2008	2009	2010	Total
Referrals Submitted	27	11	9	3	50
Opinions Reached	14	6	14	6	40

<b>Establishment of MRLs for new substances</b>					
	95-07	2008	2009	2010	Total
Submitted	65	1	4	2	72
Withdrawals	5	0	0	0	5
Positive Opinions <sup>1</sup>	52	2	2	1	57
Negative Opinions <sup>2</sup>	6	1	0	0	7

<b>Extensions / Modifications/Extrapolations of MRLs</b>					
	95-07	2008	2009	2010	Total
Submitted	96	2	2	1	101
Withdrawals	4	0	0	0	4
Positive Opinions <sup>3</sup>	111	2	3	0	116
Negative Opinions <sup>4</sup>	6	0	0	0	6
Extrapolations	45	5	0	0	50

<sup>1</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits

<sup>2</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

## CVMP Opinions in 2010 on establishment of MRLs for new substances

### Positive Opinions

<ul style="list-style-type: none"> <li>• <b>Substance INN</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>Therapeutic area</b></li> <li>• <b>Target species</b></li> </ul>	<ul style="list-style-type: none"> <li>• <b>EMA/CVMP Validation</b></li> <li>• <b>Opinion</b></li> <li>• <b>Active time</b></li> <li>• <b>Clock stop</b></li> </ul>	<b>European Commission</b> <ul style="list-style-type: none"> <li>• <b>Opinion received</b></li> <li>• <b>Date of regulation</b></li> <li>• <b>Official Journal</b></li> </ul>
<ul style="list-style-type: none"> <li>• Derquantel</li> </ul>	<ul style="list-style-type: none"> <li>• Ovine</li> </ul>	<ul style="list-style-type: none"> <li>• 18/06/2009</li> <li>• 19/05/2010</li> <li>• 119</li> <li>• 206</li> </ul>	

## Arbitrations and Community Referrals in 2010

<b>Type of referral</b>	<b>Date of clock start / CVMP opinion</b>	<ul style="list-style-type: none"> <li>• <b>Product name</b></li> <li>• <b>INN</b></li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	11/02/2009 10/02/2010	<ul style="list-style-type: none"> <li>• All strengths of water soluble powders and oral solutions containing doxycycline hyclate</li> <li>• Doxycycline hyclate</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	16/04/2009 10/02/2010	<ul style="list-style-type: none"> <li>• Veterinary medicinal formulations containing colistin at 2 MIU/ml and intended for administration in drinking water to any food producing species</li> <li>• Colistin sulfate</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	13/05/2009 10/03/2010 (after re-examination)	<ul style="list-style-type: none"> <li>• Veterinary medicinal products containing quinolones or fluoroquinolones for all food-producing species</li> <li>• Quinolones / fluoroquinolones</li> </ul>
Referral under Art. 33(4) of Directive 2001/82/EC	12/11/2008 11/11/2009 (after re-examination)	<ul style="list-style-type: none"> <li>• Tildren 500 mg</li> <li>• Tiludronic acid (as disodium salt)</li> </ul>
Referral under Art. 6(12) of Regulation (EC) No 1084/2003	14/10/2009 19/05/2010	<ul style="list-style-type: none"> <li>• Porcilis PRRS</li> <li>• Live attenuated PRRS virus strain DV</li> </ul>
Referral under Art. 6(12) of Regulation (EC) No 1084/2003	14/10/2009 19/05/2010	<ul style="list-style-type: none"> <li>• Porcilis M Hyo</li> <li>• Inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11</li> </ul>

<b>Type of referral</b>	<b>Date of clock start / CVMP opinion</b>	<ul style="list-style-type: none"> <li>• <b>Product name</b></li> <li>• <b>INN</b></li> </ul>
Referral under Art. 34 of Directive 2001/82/EC	11/11/2009	<ul style="list-style-type: none"> <li>• Fortekor vet and associated names</li> <li>• Benazepril hydrochloride</li> </ul>
Referral under Art. 34 of Directive 2001/82/EC	15/10/2008 10/03/2010	<ul style="list-style-type: none"> <li>• Tiamutin premix</li> <li>• Tiamulin fumarate</li> </ul>
Referral under Art. 34 of Directive 2001/82/EC	14/04/2010	<ul style="list-style-type: none"> <li>• Synulox Lactating Cow and associated names</li> <li>• Amoxicillin, clavulanic acid, prednisolone</li> </ul>
Procedure under Art. 78 of Directive 2001/82/EC	19/05/2010	<ul style="list-style-type: none"> <li>• Pregsure BVD and associated names</li> <li>• Inactivated Bovine Viral Diarrhoea (BVD) type 1 virus</li> </ul>
Procedure under Art. 30(3) of Regulation 726/2004	19/05/2010	<ul style="list-style-type: none"> <li>• Retrovirus RD114 in relation to live attenuated vaccines for use in dogs and cats</li> <li>• N/a</li> </ul>

## Guidelines and Working Documents in 2010

### CVMP Efficacy

Reference number	Document title	Status
EMA/CVMP/EWP/62867/2009	Concept Paper on proposed revision to the guideline for the conduct of efficacy studies for NSAIDs	Adopted for consultation, May 2010  (End of consultation 31 August 2010)

### CVMP Environmental Risk Assessment (ERA)

Reference number	Document title	Status
EMA/CVMP/ERA/430327/2009-CONSULTATION	Guideline on degradation of veterinary medicinal products in manure	Adopted for consultation, February 2010  (End of consultation, 31 August 2010)

### CVMP Immunologicals

Reference number	Document title	Status
EMA/CVMP/IWP/58879/2010	Reflection paper on data requirements for swine influenza vaccines against pandemic (H1N1) 2009 influenza	Adopted, February 2010
EMA/CVMP/IWP/105506/2007	Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD)	Adopted, March 2010
EMA/CVMP/IWP/43283/2010	Recommendation on the submission of multi-strain dossier applications for vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD)	Adopted, March 2010
EMA/CVMP/IWP/250147/2008	Guideline on data requirements to support in-use stability claims for veterinary vaccines	Adopted, March 2010
EMA/CVMP/IWP/582970/2009	Reflection paper on control of the active substance in the finished product for immunological veterinary medicinal products (IVMPs)	Adopted, March 2010
EMA/CVMP/IWP/439467/2007	Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals	Adopted, March 2010

<b>Reference number</b>	<b>Document title</b>	<b>Status</b>
EMA/CVMP/IWP/123243/2006-Rev.2	Guideline on data requirements for immunological veterinary medicinal products intended for Minor Use or Minor Species/ Limited markets	Adopted, April 2010

### **CVMP Pharmacovigilance**

<b>Reference number</b>	<b>Document title</b>	<b>Status</b>
EMA/CVMP/PhVWP/729768/2009	Veterinary Pharmacovigilance 2009 Public Bulletin	Adopted, February 2010
EMA/CVMP/PhVWP/471721/2006	Recommendation for the basic surveillance of Eudravigilance Veterinary data	Adopted for consultation, May 2010 (End of consultation, 30 November 2010)

### **Joint CHMP/CVMP Quality**

<b>Reference number</b>	<b>Document title</b>	<b>Status</b>
EMA/CHMP/CVMP/QWP/809114/2009	Concept paper on the revision of the guideline on process validation	Adopted for consultation, January 2010 (End of consultation, April 2010)
EMA/63033/2010	Concept Paper on the need for revision of the guideline on stability testing for applications for variations to a marketing authorisation	Adopted for consultation, February 2010 (End of consultation, 30 April 2010)
EMA/CHMP/CVMP/QWP/80386/2010	Questions and Answers concerning stability issues of pharmaceutical bulk products used in the manufacture of drug products	Adopted, February 2010
EMA/CVMP/VICH/502/1999-Rev.1	VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients	Adopted for consultation, May 2010 (End of consultation 31 October 2010)
EMA/CVMP/VICH/581467/2007	VICH GL 45 quality: bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products	Adopted, May 2010

**CVMP Safety**

<b>Reference number</b>	<b>Document title</b>	<b>Status</b>
EMA/CVMP/SWP/543/03-Rev.1	Guideline on user safety for pharmaceutical veterinary medicinal products	Adopted, March 2010

**General**

<b>Reference number</b>	<b>Document title</b>	<b>Status</b>
SOP/EMA/85634/2006-Rev.1	Standard Operating Procedure (SOP) on Evaluation procedure for applications and requests for the establishment of Maximum Residue Limits (MRLs) under Articles 3, 9, 10 and 15 of Regulation (EC) 470/2009	Adopted, February 2010